Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial
Open Access
Abstract
Objective We aimed to test the hypothesis that automated fibrosis score calculation and electronic reminder messages could increase the detection of advanced liver disease in patients with type 2 diabetes. Design In this pragmatic randomised controlled trial at five general medical or diabetes clinics in Hong Kong and Malaysia, we randomly assigned patients in a 1:1 ratio to the intervention group with Fibrosis-4 index and aspartate aminotransferase-to-platelet ratio index automatically calculated based on routine blood tests, followed by electronic reminder messages to alert clinicians of abnormal results, or the control group with usual care. The primary outcome was the proportion of patients with increased fibrosis scores who received appropriate care (referred for hepatology care or specific fibrosis assessment) within 1 year. Results Between May 2020 and Oct 2021, 1379 patients were screened, of whom 533 and 528 were assigned to the intervention and control groups, respectively. A total of 55 out of 165 (33.3%) patients with increased fibrosis scores in the intervention group received appropriate care, compared with 4 of 131 (3.1%) patients in the control group (difference 30.2% (95% CI 22.4% to 38%); pConclusion Automated fibrosis score calculation and electronic reminders can increase referral of patients with type 2 diabetes and abnormal fibrosis scores at non-hepatology settings. Trial registration number NCT04241575.Keywords
Funding Information
- The Chinese University of Hong Kong (2021.027)
This publication has 33 references indexed in Scilit:
- Screening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastographyJournal of Gastroenterology and Hepatology, 2018
- Noninvasive biomarkers in NAFLD and NASH — current progress and future promiseNature Reviews Gastroenterology & Hepatology, 2018
- Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of FibrosisClinical Gastroenterology and Hepatology, 2017
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD FibrosisAmerican Journal of Gastroenterology, 2017
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver diseaseJournal of Hepatology, 2016
- Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort studyGut, 2015
- Improved Surveillance for Hepatocellular Carcinoma With a Primary Care–Oriented Clinical ReminderClinical Gastroenterology and Hepatology, 2015
- Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastographyGut, 2011
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003